DIANA O'NEIL: Open Payments
NPI 1982861720 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,481 in 135 payments from 10 companies in 2025. Trend: 2023 $182 · 2024 $580 · 2025 $1,481
Food & beverage: $1,481
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 95 | $639 |
| ABBVIE INC. | 11 | $196 |
| E.R. Squibb & Sons, L.L.C. | 6 | $186 |
| Janssen Pharmaceuticals, Inc | 4 | $103 |
| Alkermes, Inc. | 4 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: INGREZZA, VRAYLAR, COBENFY, INVEGA, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII, TRINTELLIX.
Industry payments across FL — which companies pay providers there.
